Bay Area exec loses groundbreaking 'shadow trading' trial
-----
A Bay Area biotech executive committed insider trading when he used internal information to bet on a rival company, a San Francisco jury decided Friday.The case centers around trades that former Medivation executive Matthew Panuwat made in 2016, after learning that his employer, a San Francisco-based pharmaceutical company focused on cancer drugs, had received a $14 billion acquisition offer from medical giant Pfizer. "Within minutes" of hearing about the bid, according to a complaint
